Deepak Srivastava, MD
President
We’re blending the latest genomics and genome-engineering technologies with immunology research to engineer the human immune system for therapeutic benefit.
We’re advancing breakthrough science to understand, prevent, and repair heart disease by combining genetics, stem cell biology, and cutting-edge technologies.
We’re creating some of the world’s most advanced molecular tools and AI models in biomedical research, using them to decode complex biological data, accelerate discovery, and reveal new paths to prevent, diagnose, and treat devastating diseases.
We study how microbes interact with the human body to prevent, detect, and treat infectious diseases, from everyday infections to global pandemics.
We uncover shared mechanisms of brain disease to develop transformative therapies for neurodegenerative, neuroinflammatory, and complex neurological disorders.
Scientists in 36 Carefully Curated Labs
Nobel Laureates
Members of the National Academy of Medicine
Papers Published Annually
Spinout Companies With Over $1B Investment
We do science differently. Streamlined leadership, shared resources, and a culture of curiosity let experts collaborate freely across institutes.
We’ve built teams of the world’s top researchers and physician-scientists who work collaboratively to tackle the biggest diseases, with an eye for clinical success.
We’re situated in the middle of three world-class Bay Area institutions with which we have strong research affiliations: UC San Francisco (a partner since our founding in 1979), UC Berkeley, and Stanford University. We’re also connected to the region’s thriving biotech and venture capital ecosystem, which helps translate our discoveries into medicines.
Gladstone empowers emerging scientists with the skills and visionary mindset to pioneer major discoveries, unlock the next wave of medicines, and shape how we treat disease.
A collaborative, generous culture allows great science to happen faster and with greater impact.
Discovery is only the beginning. Through our connections with the broader biomedical community, we translate groundbreaking basic science into therapies that improve—and save—patients’ lives.
We’ve now entered an era where it’s possible to contemplate cures—not just treatments. At Gladstone, we’re creating technologies to accelerate discovery and, ultimately, transform medicine.
A new discovery reveals how a SARS-CoV-2 protein reprograms immune cells to accelerate viral spread—and points to a new strategy for therapeutic intervention.
The fellowship provides three years of funding for graduate students pursuing groundbreaking immunology research.
Takahashi is recognized for his pioneering work translating iPS cell technology into a clinically approved therapy for Parkinson’s disease.
An unprecedented map of 22 million immune cells provides the functional rulebook for virtual biology and next-generation immunotherapies.
Our people are our most important asset. We offer a wide array of career opportunities both in our administrative offices and in our labs.
Open PositionsDiscoveries don’t stay in our labs. Gladstone facilitates spinout companies to advance promising therapies, shortening the path between scientific discovery and helping real patients
Learn MoreYour gift to Gladstone will allow our researchers to pursue high-quality science, focus on disease, and train the next generation of scientific thought leaders.
Donate Now
